Suzhou's CStone Pharma reported China's NMPA accepted for review its NDA for Gavreto® (pralsetinib) to treat advanced or metastatic RET-altered thyroid cancer. In March, the NMPA approved pralsetinib to treat RET fusion-positive non-small cell lung cancer (NSCLC) after platinum-based chemotherapy. Discovered by CStone's partner Blueprint Medicines, Gavreto® is approved in the US and is the first approved selective RET inhibitor in  China . In 2018, CStone acquired China rights to three cancer candidates from Boston 's Blueprint in a $386 million deal. More details.... Stock Symbol: (HK: 2616) Share this with colleagues: // //